| Public | NASDAQ:TSRO |
| Date | 3/12 |
| Post IPO Valuation | $86.3M |
| Website | tesarobio.com |
| Category | BioTech |
| Phone | 339.970.0900 |
| Employees | |
| Founded | 3/10 |
| TOTAL | $161M |
| VENTURE FUNDING TOTAL | $161M |
| Series A, 5/10 New Enterprise Associates | $60M |
| Series B, 6/11 Kleiner Perkins Caufield & Byers New Enterprise Associates InterWest Partners T. Rowe Price Pappas Ventures | $101M |
Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.
